UK markets open in 4 hours 10 minutes

Immuneering Corporation (IMRX)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
1.5500+0.0100 (+0.65%)
At close: 04:00PM EDT
1.4800 -0.07 (-4.52%)
After hours: 06:22PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close1.5400
Open1.5500
Bid1.5000 x 100
Ask1.5800 x 100
Day's range1.4500 - 1.5900
52-week range1.3800 - 11.9200
Volume295,497
Avg. volume789,324
Market cap45.963M
Beta (5Y monthly)-0.60
PE ratio (TTM)N/A
EPS (TTM)-1.8700
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est11.64
  • GlobeNewswire

    Immuneering Reports First Quarter 2024 Financial Results and Provides Business Updates

    - Reported Positive Topline Results from Phase 1 Portion of its Phase 1/2a Clinical Trial of IMM-1-104 in RAS-Mutant Solid Tumors - - First Patient Dosed in Phase 2a Portion of Phase 1/2a Clinical Trial of IMM-1-104; Initial Data from Multiple IMM-1-104 Phase 2a Arms Expected in 2024 - - Presented Preclinical Data at AACR Demonstrating that Combining IMM-1-104 with Chemotherapies Used in The Treatment of First-line Pancreatic Cancer Yielded Deeper and More Durable Tumor Growth Inhibition Than Ei

  • Simply Wall St.

    We Think Immuneering (NASDAQ:IMRX) Needs To Drive Business Growth Carefully

    We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...

  • GlobeNewswire

    Immuneering Recognizes Melanoma Awareness Month

    - Two clinical stage product candidates in development for the treatment of melanoma - - RAS mutant melanoma represents one of five arms in the company’s ongoing Phase 2a clinical study of IMM-1-104 - - Melanoma also being evaluated in ongoing Phase 1/2a clinical study of IMM-6-415 in patients with advanced solid tumors harboring RAF or RAS mutations - - Immuneering expects initial data from multiple IMM-1-104 Phase 2a arms in 2024 - CAMBRIDGE, Mass., May 06, 2024 (GLOBE NEWSWIRE) -- Immuneering